ALSO NOTED: CuraGen closes facility; Stada examines takeover targets; Zentiva snags big loan; and much more...

> Continuing a plan to concentrate its efforts on pipeline development, CuraGen announced that it is closing a production facility and laying off 40 workers. The move leaves the company with 50 workers, down from 550 in 2000. Release

> Germany's Stada told investors at its annual meeting that the drug company is considering some new acquisitions, but hadn't found any buyout opportunities yet that were worth the asking price. Report

> Zentiva has completed a €550 million loan needed to acquire a majority stake in Eczacibasi Generic Pharmaceuticals. Report

> The FDA has approved Galderma's Differin Gel, 0.3%, a new, higher concentration formulation of Differin for acne. Release

> Auriga Laboratories has formed Advanced Topical Solutions, a new division with a 46 person national sales team dedicated primarily to dermatologists. Release

And Finally... Takeda Pharmaceuticals North America, Baxter Healthcare, Astellas, and other corporate donors today announced their support for biotechnology education and entrepreneurship in Illinois through gifts totaling nearly $1 million to the iBIO Institute. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.